US appeal overturns IMS "free speech" case

15 December 2008

Freedom of speech cannot be used as a defense against a US state's right to legislate against the commercial use of prescriber-identifiable data, according to the latest ruling by the US Court of Appeals for the First Circuit in Boston, Massachusetts. This overturned the verdict of the District Court which had supported health data giant IMS Health's case against New Hampshire (Marketletter May 14, 2007).

The firm said it is "currently reviewing the decision and evaluating potential options." Realistically, the choices would appear to be a US Supreme Court Appeal, to negotiate a softening of New Hampshire's regulation, or to accept that other states will follow, to the detriment of IMS' business.

The northeastern state was the first to pass a law that restricted access to prescribing data. Two of New Hampshire's neighbors, Maine and Vermont, followed suit. A federal court blocked the enforcement of Maine's legislative action in December last year, while Vermont has "temporarily repealed" its own measures until July 1, 2009, to allow legal hurdles to be cleared. IMS' challenge to Vermont's data mining restrictions was heard in a federal court in July 2008.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight